Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck

Cancer Science

Volumn 102, Issue 2, 2011, Pages 419-424

  Tahara, Makoto ^a   Minami, Hironobu ^a,b   Kawashima, Mitsuhiko ^a   Kawada, Kenji ^a,c   Mukai, Hirofumi ^a   Sakuraba, Minoru ^a   Matsuura, Kazuto ^a,d   Ogino, Takashi ^a   Hayashi, Ryuichi ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d Miyagi Cancer Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; CREATININE; FLUOROURACIL; OXONATE POTASSIUM; TEGAFUR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEEDING APPARATUS; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INOPERABLE CANCER; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; OROPHARYNX CARCINOMA; PHARYNX CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVARY GLAND; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUSPENSION; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAPSULES; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; RADIOTHERAPY; SUSPENSIONS; TEGAFUR;

EID: 79952074455     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01799.x     Document Type: Article

References (24)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41.
2. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-89.
3. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
4. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001; 28: 1381-90.
5. Fujii M, Tomita K, Nishijima W et al. Phase I/II Study of S-1 plus Cisplatin Combination Chemotherapy in Patients with Advanced/Recurrent Head and Neck Cancer. Jpn J Clin Oncol 2010; 40: 214-21.
6. Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004; 40: 713-9.
7. Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010; 24: 1307-13.
8. Fukushima M, Ohshita H, Taguchi T Combined therapy with radiation and S-1, an oral new 5FU prodrug, is markedly effective against non-small cell lung cancer xenografts in mice. Eur J Cancer 2005; Supplements 3: 343.
9. Matsushima E, Yoshida K, Kitamura R. Determination of S-1 (combined drug of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997; 691: 95-104.
10. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
11. Nakamura K, Tahara M, Kiyota N et al. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706). Jpn J Clin Oncol 2009; 39: 460-3.
12. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. 2009 ASCO Annual Meeting. Orlando, FL: Supplement to Journal of Clinical Oncology, 2009; 204s (abstract 4511).
13. Milano G, Roman P, Khater R, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988; 41: 537-41.
14. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-51.
15. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978; 38: 719-24.
16. Konno H, Tanaka T, Baba M et al. Therapeutic effect of 1M tegafur-0.4M 5-chloro-2, 4-dihydroxypyridine-1M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 1999; 90: 448-53.
17. van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-9.
18. Cohen SJ, Leichman CG, Yeslow G et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8: 2116-22.
19. McLaughlin BT, Gokhale AS, Shuai Y et al. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience. Laryngoscope 2010; 120: 71-5.
20. van der Weide J, Steijns LS Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36 (Pt 6): 722-9.
21. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76.
22. Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299-306.
23. Ikeda K, Yoshisue K, Matsushima E et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 4409-15.
24. Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957-65.